A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma

LESSONS LEARNED: Our results highlight additional toxicities of dual PI3K/mTOR inhibition in the clinical setting that were unforeseen from preclinical models. Because of toxicity and lack of efficacy, BEZ235 should not be further developed in the current formulation for patients with renal cell car...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Autores principales: Carlo, Maria I., Molina, Ana M., Lakhman, Yulia, Patil, Sujata, Woo, Kaitlin, DeLuca, John, Lee, Chung-Han, Hsieh, James J., Feldman, Darren R., Motzer, Robert J., H. Voss, Martin
Formato: Artigo
Lenguaje:Inglês
Publicado: AlphaMed Press 2016
Materias:
Clinical Trial Results
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4943396/
https://ncbi.nlm.nih.gov/pubmed/27286790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0145
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares